SMILE

First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

Retrieved on: 
Thursday, April 11, 2024
PS, FDA, Ciliary muscle, Patient, IOL, SPA, Food, DSM-IV codes, OCUP, RK, Viatris, Aberration, Protocol, GLARE, Keratoconus, SMILE, Ophthalmology, Pupil, Visual acuity, Pharmaceutical industry

FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.

Key Points: 
  • “We are pleased to begin enrollment in the LYNX-2 study of PS,” said George Magrath, M.D., M.B.A., M.S., CEO of Ocuphire.
  • Patients experience decreased low contrast visual acuity as well as glare, halos and starbursts.
  • There are currently no FDA-approved treatments for visual disturbances under low light conditions.
  • LYNX-2 is a randomized, double-masked, placebo-controlled Phase 3 registration study designed to evaluate the safety and efficacy of PS compared to placebo in subjects who underwent keratorefractive surgery and then reported decreased visual acuity under low light conditions.

CareQuest Innovation Partners and MATTER Open Applications for SMILE Health, Seeking Innovators Bridging the Medical-Dental Divide

Retrieved on: 
Wednesday, March 27, 2024
Health, Practice Management, Health Insurance, Dental, Managed Care, General Health, Equitable, Colgate-Palmolive, SMILE, Dentistry, Conference, Organization, Growth, Sun Life Financial, Health equity, Partnership, Risk, Integration, Patient, History, Schein, Medicine, Overalls, Delta Dental, Cigna, Curriculum, Multimedia, Feedback

CareQuest Innovation Partners , a company focused on validating and scaling transformative solutions to improve overall health through oral health for all, in partnership with MATTER , the premier health care incubator and innovation hub, today announced applications are open for SMILE Health.

Key Points: 
  • CareQuest Innovation Partners , a company focused on validating and scaling transformative solutions to improve overall health through oral health for all, in partnership with MATTER , the premier health care incubator and innovation hub, today announced applications are open for SMILE Health.
  • SMILE Health advances solutions to help address this gap by bringing together innovators with industry partners and investors.
  • Reducing Disparities through Oral Health: How can we leverage innovative oral health solutions to better identify and/or address health disparities?
  • We are thrilled to continue our collaboration with CareQuest Innovation Partners to build this year’s program,” said Steven Collens, CEO of MATTER.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Thursday, March 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Thursday, March 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

Food and Beverage Name-branding Agency Eat My Words Presents "The Love Your Name Award" at the Natural Products Expo West Show

Retrieved on: 
Wednesday, March 20, 2024
Dopamine, SMILE, Attention, The Wall Street Journal, Love, Brain, Serotonin, Philosophy, Name, Mac, SAN, Social media, Allergy, Food, Wendy's, Church, Marketing, Publication, Endorphins

SAN DIEGO, March 20, 2024 /PRNewswire/ -- Boutique naming firm Eat My Words ( www.eatmywords.com ) recently presented the "The Love Your Name Award" to 10 companies at the Expo West Natural Foods Show.

Key Points: 
  • SAN DIEGO, March 20, 2024 /PRNewswire/ -- Boutique naming firm Eat My Words ( www.eatmywords.com ) recently presented the "The Love Your Name Award" to 10 companies at the Expo West Natural Foods Show.
  • If you have a name that people love before they even try the product, you're golden," said Alexandra Watkins, the aptly named "Big Cheese" of Eat My Words.
  • "When someone sees a brand name that makes them break out in a grin, their brain releases positive neurotransmitters, including dopamine, endorphins, and serotonin.
  • These 10 names were determined to be the cream of the crop of the more than 3,000 brands exhibiting at Expo West.

Kao Rated Triple-A for Climate Change, Water Security, and Forests for Fourth Consecutive Year by CDP

Retrieved on: 
Tuesday, February 6, 2024
Professional Services, Other Natural Resources, Sustainability, Forest Products, Agriculture, Natural Resources, Environment, Cosmetics, Retail, Packaging, Climate Change, Environmental, Social and Governance (ESG), Manufacturing, Multimedia, Stick, Climate change, ESG, Kao Corporation, RSPO, Palm oil, Biomass, Water, Disclosure, Carbon, CO2, CDP, SMILE, Climate, Water security, A-list, Dashboard

Kao, a leading manufacturer of personal care, household, and cosmetics products, received the highest triple-A score for its sustainability initiatives involving climate change, forests, and water security.

Key Points: 
  • Kao, a leading manufacturer of personal care, household, and cosmetics products, received the highest triple-A score for its sustainability initiatives involving climate change, forests, and water security.
  • More than 21,000 firms were evaluated for the ‘A List’, with only 10 selected for inclusion across the three categories.
  • Kao has now been included in the Climate Change ‘A List’ for the fifth time, the Forests ‘A List’ for the fourth time, and the Water Security ‘A List’ for the seventh time.
  • In the forests area, Kao has created a “Palm Oil Dashboard” on its website, which provides information on its palm oil procurement activities.

NVISION Continues Expansion in Texas with Parkhurst NuVision Joint Venture

Retrieved on: 
Thursday, January 18, 2024
Health, Optical, Surgery, Optometry, Intraocular lens, Philosophy, Patient, Ophthalmology, RLE, NVISION, Outpatient surgery, Contact, EVO, Partnership, Patient First, SMILE, Joint venture, FDA, Nvision, Surgeon, PNV, Growth

NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels.

Key Points: 
  • NVISION Eye Centers, a national leader in eye care services, is proud to announce its continued expansion in Texas with a new Joint Venture partnership with Parkhurst NuVision in San Antonio and New Braunfels.
  • Parkhurst NuVision (PNV) was founded in 2013 by Dr. Gregory Parkhurst.
  • NVision’s unique Joint Venture model is very different from private equity funds because at its core lies physician leadership along with substantial equity and influence.
  • “We are thrilled to partner with Dr. Parkhurst and the Parkhurst NuVision team,” said Chris Karkenny, CEO of NVISION.

EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Saturday, January 13, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

Key Points: 
  • The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
  • ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Thursday, January 11, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Thursday, January 11, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .